A Study of SDI-118 in Participants in Remission From Depression

Depression in Remission Clinical Trial

Official title:

A Phase Ib, Exploratory, Double Blind, Placebo Controlled, Parallel Group, Study of SDI-118 to Evaluate Safety, Tolerability, and Pharmacodynamics Including Cognitive Function in Male and Female Participants in Remission From Depression

Clinical Trial Details — Status: Withdrawn

Administrative data

• NCT number: NCT05212116
• Other study ID #: SYND004
• Secondary ID: 2020-003748-10
• Status: Withdrawn
• Phase: Phase 1
• Start date: September 16, 2021
• Est. completion date: March 11, 2022

Study information

• Verified date: April 2022
• Source: Syndesi Therapeutics
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a multi-center, double-blind, randomized, placebo-controlled study to determine the safety, tolerability, and pharmacodynamics of SDI-118 in a once daily (QD) dosing regimen on male and female study participants reporting with cogntive decline and who in remission from depression.

Recruitment information / eligibility

• Status: Withdrawn
• Enrollment: 0
• Est. completion date: March 11, 2022
• Est. primary completion date: March 11, 2022
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 25 Years to 55 Years

Eligibility

Inclusion Criteria:

• Male and female participants between 25 and 55 years of age (inclusive) at screening.

• Are remitted from depression.

• Have received prescribed treatment with an antidepressant or a recognised psychotherapy for depression (e.g. cognitive behaviour therapy) for a previous MDE

• Report present subjective cognitive impairment (such as difficulty concentrating, slow thinking, and difficulty in learning new things or remembering things).

• Have not been treated with antidepressants or received other psychotherapy for depression for at least six weeks prior to Screening Visit 1.

• Otherwise healthy with no clinically significant abnormalities as determined by medical history, physical examination, blood chemistry assessments, haematologic assessments, and urinalysis, measurement of vital signs, and Electrocardiogram (ECG).

• Negative serology test for human immunodeficiency virus (HIV) antibodies, hepatitis B surface antigen (HBsAg) or hepatitis C virus (HCV) antibodies at screening.

• Have a body mass index (BMI) of 18 to 36 inclusive.

• Agree not to use herbal medications (including herbal tea, St. John's Wort), within 14 days prior to study agent administration through to the final follow-up visit.

• Participants must be able and willing to give written, informed consent, indicating that they understand the purpose of and procedures required for the study and are willing to participate in the study.

• The participant, in the opinion of the investigator, is willing and able to adhere to the study visit schedule and other requirements, prohibitions and restrictions of the study.

Exclusion Criteria:

• They are left-handed.

• Have immediate recall of greater than 22 words from the International Shopping List Test (ISLT) and have delayed recall of greater than 8 words from the ISLT 15 mins after the presentation of the word list.

• Positive urine drug screen or alcohol breath test at screening or assessment visits.

• History or presence of significant neurological or psychiatric conditions except those related to MDD.

• Any suicidal ideation of type 4 or 5 in the Columbia Suicide Severity Rating Scale (C-SSRS) in the past 3 months prior to screening or at screening or baseline visit.

• Has a known clinically relevant structural brain abnormality as determined by e.g. previous MRI, or, persistent MRI imaging artefact which is judged to produce extensive imaging distortions.

• Has a disease or takes medication that could, in the investigator's and/or sponsor's opinion, interfere with the assessments of safety, tolerability, or efficacy, or interfere with the conduct or interpretation of the study.

Related Conditions & MeSH terms

• Depression
• Depression in Remission
• Depressive Disorder

Intervention

Drug:
• SDI-118
SDI-118 is presented as low dose, and high dose capsules.
• Placebo
The Matching Placebo for SDI-118 is mannitol in capsules.

Locations

Country	Name	City	State
United Kingdom	Cardiff University	Cardiff	Wales
United Kingdom	University of Manchester	Manchester	Lancashire
United Kingdom	University of Oxford	Oxford	Oxfordshire

Sponsors (2)

Lead Sponsor	Collaborator
Syndesi Therapeutics	P1vital Limited

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of participants with Adverse Events (AEs)	Adverse events (AEs) will be coded using medical dictionary for regulatory activities (MedDRA). An AE is any untoward medical occurrence in a participant administered a study drug and which does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a medical product whether or not considered related to the medical product. An AE is considered "serious" if, in the view of either the investigator or sponsor, the event: results in death, is life-threatening, results in persistent or significant disability/incapacity or substantial disruption of the ability to conduct normal life functions, results in congenital anomaly or birth defect, requires hospitalization or prolongation to hospitalization, or other medically important event.	17 days
Primary	Number of participants with laboratory value abnormalities and/or adverse events (AEs)	Number of participants with potentially clinically significant laboratory values (hematology/chemistry/urinalysis)	17 days
Primary	Number of participants with vital sign abnormalities and/or adverse events (AEs)	Number of participants with potentially clinically significant vital sign values	17 days
Primary	Number of participants with routine 12 lead electrocardiogram (ECG) abnormalities and/or Adverse Events (AEs)	Number of participants with potentially clinically significant ECG values	17 days
Primary	Number of participants with C-SSRS abnormalities and/or Adverse Events (AEs)	Number of participants with potentially clinically significant changes in C-SSRS values.	17 days
Primary	Number of participants with routine physical examination abnormalities and/or Adverse Events (AEs)	Number of participants with potentially clinically significant changes in physical examination.	17 days
Primary	Number of participants with Changes in the Cogstate Brief Battery, including abnormalities and/or Adverse Events (AEs)	Number of participants with potentially clinically significant changes in the Cogstate Brief Battery values	17 days
Primary	Number of participants with Changes in the Digital Symbol Substitution Test, including abnormalities and/or Adverse Events (AEs)	Number of participants with potentially clinically significant changes in the DSST values.	17 days
Primary	Number of participants with Changes in the Controlled Oral Word Association Test, including abnormalities and/or Adverse Events (AEs)	Number of participants with potentially clinically significant changes in the COWAT values.	17 days
Primary	Number of participants with Changes in the Category Fluency Test, including abnormalities and/or Adverse Events (AEs)	Number of participants with potentially clinically significant changes in the CFT values.	17 days
Secondary	Changes in Blood Oxygen Level Dependent (BOLD) signal	As measured by changes in deoxyhemoglobin levels driven by localized changes in brain blood flow and blood oxygenation in brain networks associated with executive function (working memory), including the prefrontal cortex, the hippocampus, and the associated limbic networks, during performance of the N-Back Tasks	17 days
Secondary	Changes in Blood Oxygen Level Dependent (BOLD) signal	As measured by changes in processing of emotional stimuli during theperformance of the FEP task.	17 days
Secondary	Performance measures associated with executive function (working memory) during the N-Back Tasks	As measured by both response accuracy and response latency between cue stimulus and detection of this cue in the presented trial stimuli.	17 days